skip to navigation

PMD Healthcare PMD Healthcare

Remote Patient Monitoring and Wellness Management Services

Remote, real-time biometric
monitoring and patient management.

Implements easily to help achieve
performance measures, improve
outcomes, and control costs.

Disease Burden

Chronic illness are a real and growing problem for the US Healthcare system. 38 million patients suffer with either COPD or Asthma and another 6 million suffer from Congestive Heart Failure. Heart disease is the leading cause of death in the US and COPD the 3rd. Cost associated with these illnesses exceed $80 billion annually with 30% of this cost driven by hospital admissions and readmissions.

  • 38 Million

    COPD Patients
  • 25.5 Million

    Asthma Patients
  • $80 Billion

    Total U.S. Costs (2008)
  • COPD 3rd Leading

    Cause of Death

Readmissions Point To The Chronic and Reoccurring Cycle For Patients:

Reoccurring Chart
  • The 30-day hospital readmission rate for COPD patients is approximately 25%
  • 41% of all hospital readmissions are COPD
  • Readmissions for COPD costs are 50% higher than the original admission
  • For the most severe patients, readmission length of stay (LOS) is twice as long (8 days) and results in 10 times higher mortality rates

A Real Issue That Needs Real Attention:

And healthcare stakeholders are taking action

2010

ACO’s are first introduced to

  • Co-ordinate care
  • Improve Quality
  • Reduce Cost
2012

Hospital Readmission Reduction Program Introduced to

  • Decrease 30 Day readmission rates
  • Reward top performers
  • Penalize excessive readmission rate
2014

Value Modifier Program Introduced to

  • Incentivize providers on quality
  • Penalize poor performers
  • Initial program focused on groups of 100+ providers
2015

Value Modifier Program Expands

  • Groups of 10+ are now included
Today

Quality focused Programs continue to expand and evolve

  • Hospital readmission penalties exceed $428m
  • ACO’s have grown to 800+
  • Value Modifier Program covers all groups from solo+

Our Solution

PMD offers a Comprehensive Solution For All Stakeholders That is:

Golfer
  • Clinically RelevantClinically Relevant
  • Easy to ImplementEasy to Implement
  • Financially SoundFinancially Sound

Simple as 1, 2, 3

Integrates 1) easy to use medical devices,
2) HIPAA-compliant data portal, and 3) comprehensive wellness management services

  • Medical Devices Collect Biometric Data: 1

    Medical Devices Collect Biometric Data:

    Portable, WIFI enabled, easy to use medical devices wirelessly capture biometric data, symptoms, and medication adherence and care plan compliance in real time.

  • WIFI Enabled Medical Devices Deliver Biometric Data to the PMD Portal: 2

    WIFI Enabled Medical Devices Deliver Biometric Data to the PMD Portal:

    HIPAA-compliant, patient-controlled

    Beyond archiving and offering access to data, the secure, HIPAA-compliant PMD Portal connects patients and their healthcare team to improve communications...and outcomes. Patients decide who gets their data for assessment of care needs in real time and revisions of care plans based on real-time evidence.

  • WMS Promotes Care Plan Compliance for Improved Outcomes: 3

    WMS Promotes Care Plan Compliance for Improved Outcomes:

    WMS delivers a critically important, remote, real-time biometric monitoring, medication adherence and symptom monitoring service that improves communication, increases care plan compliance and provides the documentation necessary to report on quality measures and patient outcomes.

    WMS disseminates data to HCP’s, patients, and caregivers through customized alerts, email, or text messages which are aligned to personalized and customized care plans. Non-face to face time spent by care team members is properly documented for use in medical billing as appropriate.

PMD Healthcare Addresses the Most Critical Pain Points for Providers

  • Monitors

    Biometrics
    Symptoms
    Medication Adherence
    Care Plan Compliance

  • Enhances Care Coordination

    HIPAA Compliant
    Personalized Care Plans
    Real Time Interventions

  • Reduces Readmissions

    By early recognition of worsening
    Symptoms
    Biometrics
    Identification of medication noncompliance
    Reduced costly ER visits

  • Promotes Financial Benefits

    Helps Achieve Quality Measures
    Improves Outcomes
    Supports CCM Reimbursement
    Reduce Penalties

Evidence of Benefits

PMD Healthcare is well established and utilized among some of
the largest Health-Systems across the United States

U.S. Map Marked

Approved With A Large Global Presence

World Map

There is a growing body of evidence in support of what we do

copd-study-1-graph

Original Research Feasibility and Acute Care Utilization Outcomes of a Post-Acute Transitional Tele-monitoring Program (COPD/HF)

Background

COPD and Heart Failure are chronic diseases that impart significant healthcare costs on the patient and health system.

Methods

The intervention was a prospective 90 day transitional care program following an acute event that integrated a mobile health technology and home visits for patients with COPD and/or Heart Failure.

Results

The 30 day readmission rates were reduced by 50% for both COPD and Heart Failure patients versus the control group.

The program was feasible and satisfactory to patients with daily adherence greater than 70%.

Patients sustained clinically meaningful improvements 
in their health status.

 

TELEMEDICINE and e-HEALTH SEPTEMBER 2015

Original Research Feasibility and Acute Care Utilization Outcomes of a Post-Acute Transitional Tele-monitoring Program (COPD/HF)

copd-study-2-graphs

TELEMEDICINE and e-HEALTH SEPTEMBER 2015

A pilot study of a mobile-phone-based home monitoring system to assist in remote interventions in cases of acute exacerbation of COPD

Background

Patients with COPD often suffer from Acute Exacerbations (AECOPD), a sudden worsening of respiratory symptoms such as dyspnea and sputum. In the management of patients with COPD, timely intervention of AECOPD is important because exacerbations are responsible for gradual but irreversible progression of the disease and often require emergency department (ED) treatment. However, in practice patients with AECOPD often take the ‘‘wait and see’’ approach, and some of them fail to receive treatment, probably due to the unmet needs for health care.

Methods

We conducted a six-month feasibility study of a mobile-phone-based home monitoring system, called M-COPD. Patients with a history of moderate Acute Exacerbation of COPD (AECOPD) were given a mobile phone to record major symptoms (dyspnea, sputum color and volume), minor symptoms (cough and wheezing) and vital signs. A care team remotely monitored the recorded data and provided clinical interventions.

Results

There were significantly lower hospital admissions with M-COPD, ED presentations and GP visits than in the matched period.

The results demonstrate the potential to analyze respiratory symptoms for early intervention of AECOPD.

Journal of Telemedicine and Telecare 2014, Vol. 20

COPD ED, Hospital and GP Visits

copd-study-3-graphs

Journal of Telemedicine and Telecare 2014, Vol. 20

The Ability of Home Spirometry and Symptom Monitoring to Predict Exacerbations in Cystic Fibrosis

Background

Patients (pts) with cystic fibrosis (CF) suffer frequent pulmonary exacerbations, diagnosed by decline in lung function and increased symptoms. Early and aggressive therapy is associated with better outcomes. 

CF pts do not usually monitor their lung function or symptoms at home, and exacerbations are only detected when pts are sick enough to seek care. The purpose of this study was to assess the feasibility of home monitoring.

Methods

This is a six month study of ten pts with CF. Each was given an electronic device to measure FEV1 twice daily and symptoms once daily. Data was transmitted to us weekly by phone, and exacerbations were scored using the Akron exacerbation scale. Medical records were examined for evidence of clinically detected exacerbations.

Results

There were 28 exacerbations detected through home monitoring, but only 8 of these were clinically detected and reported by the pts to their physicians. Home monitoring detected exacerbations an average of 15.6 days before pts contacted the care center because of symptoms.

Although these are pilot study results, the data suggests home monitoring can detect exacerbations more than two weeks before patients typically seek medical care; therefore, early intervention may improve CF outcomes.

Excerpt From Pediatric 2014, Vol. 34, 532 “Poster Session Abstract” poster 376

The Ability of Home Spirometry and Symptom Monitoring to Predict Exacerbations in Cystic Fibrosis

JOHNS HOPKINS RESEARCH DEPARTMENT — PULMONOLOGISTS NOAH LECHTZIN AND NATALIE WEST 

Spirometry detected exacerbations an average of 16 days before patients began to feel symptoms.

…patients gained insight into their health through the use of home spirometry and were able to take steps to maintain their health through better medication adherence and better adherence with airway clearance techniques.

 

Pediatric Pulmonology 2009: 44(S32):343-44

cf-study-2-graph

 

The Use of Home Spirometry in
Pediatric Cystic Fibrosis Patients: Results of a Feasibility Study

Background

Medication adherence is poor among pediatric cystic fibrosis patients. Several factors have been reported to negatively influence treatment adherence among CF patients including forgetfulness, time pressures, competing priorities, and perceived lack of usefulness of the prescribed treatment.

In order to develop an intervention that would be appealing to and potentially useful in promoting treatment adherence in this population, we surveyed adolescents and young adults in our Pediatric CF Center.

The purpose of the study was to elicit opinions about interventions that would best encourage them in improving adherence. Based upon the survey responses, we also conducted a pilot study to assess the feasibility of a portal personal spirometer device that also provided medication reminders.

Methods

The survey consisted of 2 parts.
The first part focused on eliciting
the participants’ views on their own adherence to medications. Participants were also asked abut potential adherence barriers and motivators.

In the second part of the survey, subjects were asked to generate ideas for potential adherence interventions.

The study was designed to evaluate the feasibility of home spirometry and medication reminders, the top 2 adherence intervention ideas from
the survey.

The Spiro PD (PMD Healthcare) personal spirometer was chose for monitoring of PFTs and adherence
at home.

Results

92.5% of respondents identified 2 or more factors that positively influenced their adherence. 72.5% of respondents reported encouragement from their parents, other family members and friends as an adherence facilitator.  Frequent monitoring of PFTs as an adherence intervention was endorsed by 31 ( 77.5%) of respondents with
29 of them (93.5%) supporting home spirometry. Twenty two of the 24 respondents that chose medication reminders as an intervention recommended implementing them either as a text message of smart phone application.

Mean percent adherence to weekly spirometry was 94.67%/

The intervention group maintained their BMI and had an increase in their PFT’s.

A Shakkottai M.D., A Nasrallah, SZ Nasr M.D., C.P.I.1
1Department of Pediatrics and Communicable Diseases, University of Michigan Health System Global Pediatric Health Volume 4:1-6 2017

The Use of Home Spirometry in
Pediatric Cystic Fibrosis Patients: Results of a Feasibility Study

Mean FEV1 and FEF25-75 % predicted at baseline and 3-months in the intervention and control groups. The intervention group experienced a 3% increase in FEV1 and a 5% increase in FEF25-75. The control group had a 2% decline in FEV1 and a 15% decline in FEF25-75 % predicted.

A Shakkottai M.D., A Nasrallah, SZ Nasr M.D., C.P.I.1
1Department of Pediatrics and Communicable Diseases, University of Michigan Health System Global Pediatric Health Volume 4:1-6 2017

The Use of Home Spirometry in Pediatric Cystic Fibrosis Patients:Results of a Feasibility Study

Mean treatment burden scores in the intervention and control groups at enrollment and 3-months. In the intervention group there was improvement in both the child and caregiver perceptions of treatment burden whereas in the control group there was only improvement in the caregiver perceptions of treatment burden.

A Shakkottai M.D., A Nasrallah, SZ Nasr M.D., C.P.I.1
1Department of Pediatrics and Communicable Diseases, University of Michigan Health System Global Pediatric Health Volume 4:1-6 2017

The Use of Home Spirometry in
Pediatric Cystic Fibrosis Patients: Results of a Feasibility Study

Mean medication possession rations for inhaled hypertonic saline, dornase alfa, and CF multivitamins in the intervention and control groups at baseline and end of study.

A Shakkottai M.D., A Nasrallah, SZ Nasr M.D., C.P.I.1
1Department of Pediatrics and Communicable Diseases, University of Michigan Health System Global Pediatric Health Volume 4:1-6 2017

Original Research Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis

Background

Potential clinical advantages of routine home monitoring of IPF include early detection of rapidly declining FVC (which would enable prompt assessment of patients with potential acute exacerbations) and monitoring if response to novel therapies.

The aim of this study was to
assess the feasibility, reliability, and potential value of monitoring patient administered daily FVC in a cohort of subjects with IPF.

Methods

50 subjects with IPF were recruited for the study and given handheld spirometers and instruction on how
to self-administer spirometry. Subjects recorded daily FEV1 and FVC for up to 490 days. Clinical assessment and hospital based spirometry was undertaken as 6 and 12 months, and outcome data were collected for 3 years.

Results

Home spirometry showed excellent correlation with hospital-obtained readings. The rate of decline in FVC was highly predictive of outcome and subsequent mortality when measured at 3 months and 12 months.

Daily, unsupervised, patient performed, domiciliary spirometry is highly clinically informative in individuals with IPF. Although some patients found the daily FVC unpleasant to perform, the rate of discontinuation was comparable to the dropout rates seen in clinical trials.

Furthermore the increased frequency
of measurement provided information above that obtained through periodic hospital based measurement of FVC.

 

American Journal of Respiratory and Critical Care Medicine  Volume 194 Number 8 October 15 2016

FVC Change on Subsequent Survival

Relationship between 3- and 12-month rate of FVC change and subsequent survival. Kaplan–Meier plots demonstrate the effect of rate of change in FVC on subsequent survival at (A) 3 months and (B) 12 months. At 12 months, subjects were dichotomized into those with .10% rate of decline in FVC (red line) (n = 28) or,10% FVC rate of change (blue line) (n = 22). At 3 months, subjects were dichotomized into those with .5% rate of change in FVC (red line) (n = 19) or ,5% rate of change in FVC (blue line) (n = 31). Rate of change was calculated by linear regression analysis of all points between baseline and 3 and 12 months, respectively. Rate of change is reported relative to baseline values, which were calculated by taking the mean of all the daily readings recorded by subjects during the first 7 days of the study.

 

American Journal of Respiratory and Critical Care Medicine  Volume 194 Number 8 October 15 2016

Contact us to learn more about Asthma studies.

mypmd.com/contact/

Cost Effectiveness

Remote Patient Monitoring and WMS Make Good Financial Sense!

For quality focused organizations and those in pay for performance and shared saving models, remote monitoring of biometrics, symptoms and medication adherence makes solid financial sense.

Financial Flow Chart

Work with us to enhance care coordination, improve quality, reduce readmissions and improve outcomes.

Contact us today to receive a complimentary analysis specific to your organization demonstrating the clinical benefit, ease of implementation and financial benefits.